Aurinia Pharmaceuticals (NASDAQ:AUPH) Downgraded to “Buy” Rating by StockNews.com

StockNews.com lowered shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) from a strong-buy rating to a buy rating in a research report released on Friday morning.

Other equities research analysts also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating and issued a $13.00 target price on shares of Aurinia Pharmaceuticals in a research note on Friday, September 6th. Cantor Fitzgerald reiterated an “overweight” rating and set a $10.00 price target on shares of Aurinia Pharmaceuticals in a report on Monday, September 16th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $10.00.

Aurinia Pharmaceuticals Stock Performance

NASDAQ:AUPH opened at $9.37 on Friday. The firm has a market capitalization of $1.34 billion, a PE ratio of -62.46 and a beta of 1.41. The stock’s fifty day moving average is $8.03 and its 200 day moving average is $6.75. Aurinia Pharmaceuticals has a fifty-two week low of $4.71 and a fifty-two week high of $10.67. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60.

Insider Transactions at Aurinia Pharmaceuticals

In other news, Director Jeffrey Allen Bailey sold 4,557 shares of Aurinia Pharmaceuticals stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $8.43, for a total transaction of $38,415.51. Following the completion of the sale, the director now owns 13,356 shares of the company’s stock, valued at approximately $112,591.08. The trade was a 25.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Banque Cantonale Vaudoise lifted its holdings in shares of Aurinia Pharmaceuticals by 126.6% in the 2nd quarter. Banque Cantonale Vaudoise now owns 9,684 shares of the biotechnology company’s stock worth $55,000 after buying an additional 5,410 shares during the period. B. Riley Wealth Advisors Inc. purchased a new stake in Aurinia Pharmaceuticals in the second quarter worth about $84,000. CWM LLC grew its holdings in Aurinia Pharmaceuticals by 247.7% during the 3rd quarter. CWM LLC now owns 11,483 shares of the biotechnology company’s stock worth $84,000 after acquiring an additional 8,180 shares in the last quarter. FMR LLC grew its holdings in Aurinia Pharmaceuticals by 44.8% during the 3rd quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock worth $93,000 after acquiring an additional 3,919 shares in the last quarter. Finally, PFG Investments LLC increased its position in Aurinia Pharmaceuticals by 37.9% during the 2nd quarter. PFG Investments LLC now owns 28,750 shares of the biotechnology company’s stock valued at $164,000 after purchasing an additional 7,900 shares during the period. Institutional investors own 36.83% of the company’s stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.